# Uniformity of Dosage Units (BP 2011 \& USP 34) 

Ms. Witinee Kongsuk
Bureau of Drug and Narcotic
Department of Medical Sciences
June 14, 2011

Outline :

- Definition
- Harmonized general chapter
- USP 34 <905> Uniformity of Dosage Units
- BP 2011 Appendix XII C. Consistency of Formulated Preparations

4. Uniformity of Dosage Units

- Definition of " $T$ " and " $W$ "
- Example

To ensure the consistency of the dosage units

- Each units in a batch should have a drug substance content within a narrow range around the label claim


## Definition:

"The degree of uniformity in the amount of the drug substance among dosage units"

Can be demonstrated by either of 2 methods

1. Content Uniformity (CU)
2. Mass/Weight Variation (MW), (WV)

Pharmacopoeia

- US Pharmacopeia (USP): USP 34
- British Pharmacopoeia (BP): BP 2011

USP 28-NF 23

- Harmonized general chapter <905> on page 2505-2510 with an implementation date April 1, 2006
- Approved by the Pharmacopeial Discussion Group (PDG)
- USP postponed the implementation date to January 1, 2007: USP 29

PDG:- The United States Pharmacopeia

- The Japanese Pharmacopeia
- The European Pharmacopeia

The requirements for dosage uniformity are met

- The acceptance value of the first 10 dosage units is less than or equal to L1\%.
- If the acceptance value is greater than L1\%, test the next 20 units.
- The requirements are met if the final acceptance value of the 30 dosage units is less than or equal to L1\% and all individual dosage units fall within the range calculated using L2 factor.


## Statistical basis of the new content uniformity criteria

General idea of statistical tolerance intervals:

- To use the available data to form an interval that covers a specified proportion of the distribution underlying the data.
- To form an interval about the label claim within which a specified proportion of units would fall.
- An interval is a $95 \%$ tolerance interval for $90 \%$ of the distribution if $95 \%$ of such interval with repeated sampling would cover at least $90 \%$ of the distribution.

| Dosage Form | Type | Subtype | Dose\&Ratio of Drug Substance |  |
| :---: | :---: | :---: | :---: | :---: |
|  |  |  | $\begin{aligned} & \geq 25 \mathrm{mg} \text { and } \\ & \geq 25 \% \end{aligned}$ | $\begin{aligned} & <25 \mathrm{mg} \text { or } \\ & <25 \% \end{aligned}$ |
| Tablets | Uncoated |  | WV | CU |
|  | Coated | Film | WV | CU |
|  |  | Others | Cu | CU |
| Capsules | Hard |  | WV | CU |
|  | Soft | Suspension, emulsion, or gel | CU | CU |
|  |  | Solutions | WV | WV |
| Solids in singleunit containers | Single component |  | WV | WV |
|  | Multiple components | Solution freeze-dried in final container | WV | WV |
|  |  | Others | CU | CU |
| Solutions in unitdose containers and into soft capsules |  |  | WV | WV |
| Others |  |  | CU | $\mathrm{CU}^{8}$ |

## Mass/Weight Variation (MV/WV)

Assay for the drug substance(s) on a representative sample $\longrightarrow$ result (\%la.)
Select $\geq 30$ dosage units
$\longrightarrow$ Accurately weigh 10 units individually
$\longrightarrow$ Cal. the drug substance (in \%la.) of each unit from the weight of individual unit and the result of the Assay
$\longrightarrow$ Cal. The acceptance value (AV)
**Assume that the concentration (wt. of drug substance per wt. of dosage unit) is uniform.

## Calculation of individual estimated contents

$$
X_{i}=w_{i} \times A / \bar{W}
$$

| $\mathrm{X}_{1}, \mathrm{X}_{2}, \ldots, \mathrm{X}_{\mathrm{n}}$ | $=$ | Individual estimated contents of the units tested |
| :---: | :---: | :---: |
| $\mathrm{W}_{1}, \mathrm{~W}_{2}, \ldots, \mathrm{~W}_{\mathrm{n}}$ | $=$ | Individual weights of the units tested |
| A | $=$Content of drug substance $(\%$ of label claim) <br> obtained using an appropriate analytical method |  |
| $\bar{W}$ | $=$ | Mean of individual weights $\left(W_{1}, W_{2}, \ldots, W_{n}\right)$ |

## Content Uniformity (CU)

Select $\geq 30$ dosage units and proceed as follows for the dosage form designated $\longrightarrow$ Assay 10 unit individually
$\longrightarrow$ Cal. the drug substance (in \%la.) of each unit $\longrightarrow$ Cal. The acceptance value

Where different procedures are used for Assay of the preparation and for the Content Uniformity test, it may be necessary to establish a correction factor to be applied to the results of the latter.

## Requirement of uniformity of dosage units

Acceptance value (AV) of the first 10 units is $\leq \mathrm{L} 1 \%$

$$
A V=|M-\bar{X}|+k s
$$

If AV is $>\mathrm{L} 1 \%$, test the next 20 units,
Calculate the AV
AV of 30 units is $\leq L 1 \%$
No individual content of any dosage unit is
< [1-(0.01)(L2)]M nor > [1+(0.01)(L2)]M
$\mathrm{L} 1=15.0, \mathrm{~L} 2=25.0$

Mean of individual contents $\left(X_{1}, X_{2}, \ldots, X_{n}\right)$, expressed as a percentage of the label claim
$\mathrm{X}_{1}, \mathrm{X}_{2}, \ldots, \mathrm{X}_{\mathrm{n}}$
n
k

S

M Reference value
AV Acceptance value

RSD Relative standard deviation (The sample standard deviation expressed as a percentage of the mean)

L1 Maximum allowed acceptance value, $\mathbf{L 1}=\mathbf{1 5 . 0}$ unless otherwise specified
Maximum allowed range for deviation of each dosage unit tested from the calculated value of $M$ Range:[1-(0.01)(L2)]M to [1+(0.1)(L2)]M, L2 = 25.0 unless otherwise specified.

Target content per dosage unit at the time of manufacture, expressed as a percentage of the label
Individual contents of the units tested, expressed as a percentage of the label claim

Sample size (number of units in a sample)

Acceptability constant: If $\mathbf{n}=\mathbf{1 0}$, then $\mathbf{k}=\mathbf{2 . 4}$ or If $\mathbf{n}=\mathbf{3 0}$, then $\mathbf{k}=\mathbf{2 . 0}$

Sample standard deviation claim. For purposes of this Pharmacopeia, unless otherwise stated in the individual monograph, T is $100.0 \%$, and for manufacturing purposes, T is the manufacturer's approved target test amount value at the time manufacture.

Calculation of Acceptance Value (AV) $A V=|M-\bar{X}|+k s$
if $\mathrm{n}=10$, then $\mathrm{k}=2.4$
if $\mathrm{n}=30$, then $\mathrm{k}=2.0$
M (case 1) when $\mathrm{T} \leq 101.5$

| Conditions |  | Value |
| :---: | :---: | :---: |
| If $\mathbf{9 8 . 5 \%} \leq \overline{\mathrm{X}} \leq \mathbf{1 0 1 . 5 \%}$ | $\mathrm{M}=\overline{\mathrm{X}}$ | $\mathrm{AV}=\mathrm{ks}$ |
| If $\overline{\mathrm{X}}<\mathbf{9 8 . 5 \%}$ | $\mathrm{M}=\mathbf{9 8 . 5 \%}$ | $\mathrm{AV}=\mathbf{9 8 . 5 - \overline { X } + \mathrm { ks }}$ |
| If $\overline{\mathrm{X}}>\mathbf{1 0 1 . 5 \%}$ | $\mathrm{M}=\mathbf{1 0 1 . 5 \%}$ | $\mathrm{AV}=\overline{\mathrm{X}} \mathbf{- 1 0 1 . 5}+\mathrm{ks}$ |

Acceptance Value (AV) $A V=|M-\bar{X}|+k s$

$$
\begin{aligned}
& \text { if } n=10 \text {, then } k=2.4 \\
& \text { if } n=30 \text {, then } k=2.0
\end{aligned}
$$

M (case 2) when T > 101.5

| Conditions | Value |  |
| :---: | :---: | :---: |
| If 98.5\% $\leq \bar{X} \leq T \%$ | $\mathrm{M}=\overline{\mathrm{X}}$ | AV $=\mathrm{ks}$ |
| If $\bar{X}<\mathbf{9 8 . 5 \%}$ | $\mathrm{M}=98.5 \%$ | $A V=98.5-\bar{X}+\mathrm{ks}$ |
| If $\bar{X}>$ T\% | $\mathrm{M}=\mathrm{T} \%$ | $\mathbf{A V}=\overline{\mathrm{X}}-\mathrm{T}+\mathrm{ks}$ |


| BP | Definition | USP | Definition |
| :---: | :---: | :---: | :---: |
| $\begin{aligned} & 2005 \\ & 2007 \end{aligned}$ | Target test sample amount at time of manufacture. | $\begin{aligned} & 28 \\ & 29 \\ & 30 \end{aligned}$ | Target test sample amount at time of manufacture. For purposes of this Pharmacopeia, unless otherwise specified in the individual monograph, T is $100.0 \%$, and for manufacturing purposes, T is the manufacturer's approved target test amount value at the time of manufacture. |
| 2008 | Target test sample amount at time of manufacture. | $\begin{aligned} & 31 \\ & 32 \end{aligned}$ | Target content per dosage unit at the time of manufacture, expressed as a percentage of the label claim. For purposes of this Pharmacopeia, unless otherwise specified in the individual monograph, T is the average of the limits specified in the potency definition in the individual monograph. |


| 2009 | Target content per dosage | 32 |
| :--- | :--- | :---: |
| 2010 | unit at time of manufacture, | $\left(2^{\text {nd }}\right.$ |
| 2011 | expressed as a percentage of | supp. $)$ |
|  | the label claim. T is equal to | 33 |
|  | 100 Percent unless an | 34 |
|  |  |  |

Target content per dosage unit at the time of manufacture, expressed as a percentage of the label claim. For purposes of this Pharmacopeia, unless otherwise stated in the individual monograph, T is $100.0 \%$, and for manufacturing purposes, T is the manufacturer's approved target test amount value at the time of manufacture.

## Definition of $w_{i} \& \bar{W}: \quad X_{i}=w_{i} \times A / \bar{W}$

| BP | Definition | USP | Definition |
| :---: | :---: | :---: | :---: |
| $\begin{aligned} & 2005 \\ & 2007 \end{aligned}$ | $\mathrm{w}_{1}, \mathrm{w}_{2}, \ldots, \mathrm{w}_{\mathrm{n}}=$ individual masses of the dosage units tested <br> $\overline{\mathrm{W}}=$ mean of individual masses $\left(w_{1}, w_{2}, \ldots, w_{n}\right)$ | $\begin{aligned} & 28 \\ & 29 \\ & 30 \end{aligned}$ | $\mathrm{w}_{1}, \mathrm{w}_{2}, \ldots, \mathrm{w}_{\mathrm{n}}=$ individual weights of the units tested <br> $\bar{W}=$ mean of individual weights <br> $\left(w_{1}, w_{2}, \ldots, w_{n}\right)$ |
| 2008 | $\mathrm{w}_{1}, \mathrm{w}_{2}, \ldots, \mathrm{w}_{\mathrm{n}}=$ individual masses of the dosage units tested <br> $\overline{\mathrm{W}}=$ mean of individual masses $\left(w_{1}, w_{2}, \ldots, w_{n}\right)$ | $\begin{aligned} & 31 \\ & 32 \end{aligned}$ | $w_{1}, w_{2}, \ldots, w_{n}=$ individual weights of the units tested, for weight variation <br> $\overline{\mathrm{W}}=$ mean of individual weights ( $\mathrm{w}_{1}, \mathrm{w}_{2}, \ldots, \mathrm{w}_{\mathrm{n}}$ ) of the units used n the Assay |

$2009 \mathrm{w}_{1}, \mathrm{w}_{2}, \ldots, \mathrm{w}_{\mathrm{n}}=$ individual masses of the32
$2011 \overline{\mathrm{~W}}$ = mean of individual masses of the units used in the assay
$\mathrm{w}_{1}, \mathrm{w}_{2}, \ldots, \mathrm{w}_{\mathrm{n}}=$ individual weights of the units tested
$\mathrm{W}=$ mean of individual weights $\left(w_{1}, w_{2}, \ldots, w_{n}\right)$
$\mathrm{w}_{1}, \mathrm{w}_{2}, \ldots, \mathrm{w}_{\mathrm{n}}=$ individual weights of the units tested, for weight variation
$\overline{\mathrm{W}}=$ mean of individual weights ( $w_{1}, w_{2}, \ldots, w_{n}$ ) of the units used $n$ the Assay
$\mathrm{w}_{1}, \mathrm{w}_{2}, \ldots, \mathrm{w}_{\mathrm{n}}=$ individual weights of the units tested
$\bar{W}=$ mean of individual weights
$\left(w_{1}, w_{2}, \ldots, w_{n}\right)$

Frequently asked questions
Q: What is meant by the term "special procedure" as found under Content Uniformity in the official chapter?

A: Typically, CU determination is made on individual dosage units using the procedure found in the Assay. For certain products, a separate procedure is given in the monograph for CU determination.
e.g. Clopidogrel Tablets

Theophylline Extended-Release Capsules

## Frequently asked questions

Q: What is the max. allowable acceptance value for CU testing at level 2 , where a total of 30 dosage units have been tested?

A: CU testing can be performed in 2 stages: $1^{\text {st }}$ stage ( 10 units) and $2^{\text {nd }}$ stage (total 30 units) L1 = limit for the acceptance value for both stages L2 = to calculate the allowed limits for individual dosage unit content

## Frequently asked questions

Q: If uncoated tablet contains 2 drug substances but only one of them meets the requirement for WV, how can the requirement be met?

A: In the case of a two-component tablet, uniformity of dosage units test requirement will be met by the WV for the component $\geq 25 \mathrm{mg}$ of drug substance comprising $\geq 25 \%$ of the weight of the dosage unit mass. The other component will require the CU .

## Example:

| T value | $100.0 \%$ |
| :--- | :---: |
| L1 | 15.0 |
| L2 | 25.0 |
| Average of 10 values (\%la.), $\bar{X}$ | 102.0 |
| Standard deviation of 10 values | 4.6 |
| M value: $($ If $\bar{X}>101.5 \%$ then $M=101.5)$ | 101.5 |
| AV $=\bar{X}-101.5+$ ks $=(102.0-101.5)+2.4(4.6)$ | 11.54 |
| Result | Pass |

Criteria : AV of the first 10 units is $\leq L 1 \%$

## Example:

| T value | 100.0\% |
| :---: | :---: |
| L1 | 15.0 |
| L2 | 25.0 |
| Average of 10 values (\%la.), $\bar{X}$ | 107.0 |
| Standard deviation of 10 values | 4.6 |
| $M$ value: (If $X>101.5 \%$ then $M=101.5$ ) | 101.5 |
| $\mathrm{AV}=\overline{\mathrm{X}}-101.5+\mathrm{ks}=107.0-101.5+2.4(4.6)$ | 16.54 |
| Result | Fail |
| Perform the next 20 units, total = 30 units, Average (X) | 106.5 |
| Standard deviation of 30 values | 5.2 |
| Min. value $=94.7 \%$ la and max. value $=127.1 \%$ la . |  |
| $M$ value: (If $\bar{X}>101.5 \%$ then $M=101.5$ ) | 101.5 |
| $\mathrm{AV}=\mathrm{X}-101.5+\mathrm{ks}=106.5-101.5+2.0(5.2)$ | 15.4 |
| Min. allowed range: [1-(0.01)(L2)]M | 76.1 |
| Max. allowed range: [1+(0.01)(L2)]M | 126.9 |
| Result | Fail |

USP 28 to USP34
<905> Uniformity of Dosage Units

- Content Uniformity
- Weight variation

BP 2005 and BP 2007
Appendix XII N. Uniformity of Dosage Units
(Ph.Eur. Method 2.9.40)

- Content Uniformity
- Mass Variation

Appendix XII G. Uniformity of Weight (Mass) (Ph.Eur. Method 2.9.5)
Appendix XII H. Uniformity of Content (Ph.Eur. Method 2.9.6)
Appendix XII L. Uniformity of Weight (Mass) of Delivered Doses from Multi-dose Containers (Ph.Eur. Method 2.9.27)

BP 2008 to BP 2011

Appendix XII C. Consistency of Formulated Preparations

1. Uniformity of Weight (Mass) (Ph.Eur. Method 2.9.5)
2. Uniformity of Weight (Mass) of Delivered Doses from Multidose containers (Ph.Eur. Method 2.9.27)
3. Uniformity of Content (Ph.Eur. Method 2.9.6)
4. Uniformity of Dosage Units (Ph.Eur. Method 2.9.40)

## Thank you

